In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28912151.
- Also identified by DOI 10.2967/jnumed.117.197582.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The identification of new molecular targets for diagnostic and therapeutic applications using in vitro methods is an important challenge in nuclear medicine. One such method is immunohistochemistry, increasingly popular because it is easy to perform. This review presents the case for conducting receptor immunohistochemistry to evaluate potential molecular targets in human tumor tissue sections. The focus is on the immunohistochemistry of G-protein-coupled receptors, one of the largest families of cell surface proteins, representing a major class of drug targets and thus playing an important role in nuclear medicine. This review identifies common pitfalls and challenges and provides guidelines on performing such immunohistochemical studies. An appropriate validation of the target is a prerequisite for developing robust and informative new molecular probes.
Medical subject headings
- Drug Delivery Systems
- Drug Delivery Systems/methods
- Humans
- Immunohistochemistry
- Immunohistochemistry/methods
- Neoplasms
- Neoplasms/diagnostic imaging
- Neoplasms/drug therapy
- Nuclear Medicine
- Nuclear Medicine/methods
- Receptors, Drug
- Receptors, Drug/drug effects
- Reproducibility of Results